文献速递肿瘤 PET/CT

尿激酶型纤溶酶原激活物受体PET/CT在头颈部鳞状细胞癌中的预后价值及与18F-FDG PET/CT的比较:单中心前瞻性研究

Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with 18F-FDG PET/CT: A Single-Center Prospective Study.
PubMed 文献 · J Nucl Med · 2021-12-02

这项II期临床试验(NCT02965001)前瞻性纳入57例拟接受根治性放疗的头颈部鳞状细胞癌患者,于放疗前行68Ga-uPAR PET/CT与18F-FDG PET/CT,评估原发肿瘤SUVmax的预后价值。中位随访33.8个月,68Ga-uPAR SUVmax高于 cutoff 与较差的无复发性生存(RFS)和总生存(OS)显著相关;多因素分析中仅68Ga-uPAR SUVmax对RFS保持显著。作者认为68Ga-uPAR PET可能有助于识别适合降阶梯治疗和风险分层随访的患者。

要点

  • 68Ga-uPAR PET/CT原发肿瘤SUVmax最佳cutoff为RFS 2.63、OS 2.66,高于cutoff与较差RFS和OS显著相关。
  • 单因素分析中68Ga-uPAR SUVmax与较差RFS显著相关(HR 8.53),与OS仅边缘相关(HR 7.44,P=0.052)。
  • 多因素分析中仅68Ga-uPAR SUVmax对RFS保持显著(HR 8.51),OS仅TNM分期和18F-FDG保持显著。

核心结论

  • 本试验显示,原发肿瘤68Ga-uPAR PET SUVmax在预测拟接受根治性放疗的头颈部鳞状细胞癌患者RFS方面较18F-FDG PET、TNM分期和p16状态有较好前景。
  • 68Ga-uPAR PET可能有助于识别适合降阶梯治疗和风险分层随访方案的患者。

研究设计与样本

  • 这是一项II期临床试验(NCT02965001),前瞻性纳入拟接受根治性放疗的头颈部鳞状细胞癌患者。
  • 放疗开始前行68Ga-uPAR PET/CT和18F-FDG PET/CT,由2名独立读者测量原发肿瘤SUVmax。
  • 共纳入57例患者,中位随访33.8个月(范围2.30-47.2个月)。

主要发现

  • 原发肿瘤68Ga-uPAR SUVmax中位数为2.98(范围1.94-5.24),18F-FDG SUVmax中位数为15.7(范围4.24-45.5)。
  • 68Ga-uPAR SUVmax高于cutoff与较差RFS(log-rank P=0.012)和OS(log-rank P=0.022)显著相关。
  • 单因素分析中68Ga-uPAR摄取与较差RFS显著相关(HR 8.53,95%CI 1.12-64.7,P=0.038),与OS边缘相关(HR 7.44,95%CI 0.98-56.4,P=0.052)。
  • 18F-FDG SUVmax高于cutoff与RFS降低(log-rank P=0.012)和OS降低(log-rank P=0.000)显著相关;单因素分析中18F-FDG摄取与较差RFS(HR 3.27,95%CI 1.237-8.66,P=0.017)和OS(HR 7.10,95%CI 2.60-19.4,P<0.001)显著相关。
  • 多因素分析(纳入68Ga-uPAR SUVmax、18F-FDG SUVmax、TNM分期和p16状态)中,仅68Ga-uPAR SUVmax对RFS保持显著(HR 8.51,95%CI 1.08-66.9,P=0.042);对OS仅TNM分期和18F-FDG保持显著。

关键数值与推荐

  • 68Ga-uPAR PET/CT原发肿瘤SUVmax最佳cutoff:RFS为2.63,OS为2.66。
  • 18F-FDG PET/CT原发肿瘤SUVmax最佳cutoff:RFS为22.7,OS为22.9。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this phase II clinical trial (NCT02965001) was to evaluate the prognostic value of urokinase-type plasminogen activator receptor (uPAR) PET/CT with the novel ligand 68Ga-NOTA-AE105 in head and neck cancer and compare it with 18F-FDG. Methods: Patients with head and neck squamous cell carcinoma referred for curatively intended radiotherapy were eligible and prospectively included in this study. 68Ga-uPAR and 18F-FDG PET/CT were performed before initiation of curatively intended radiotherapy, and the SUVmax of the primary tumor was measured on both PET/CT studies by 2 independent readers. Relapse-free survival (RFS) and overall survival (OS) were calculated, and optimal cutoffs were established for 68Ga-uPAR and 18F-FDG PET independently and compared using log rank and Kaplan-Meier statistics, as well as univariate and multivariate analysis in a Cox proportional-hazards model. Results: In total, 57 patients were included and followed for a median of 33.8 mo (range, 2.30-47.2, mo). The median SUVmax of the primary tumors was 2.98 (range, 1.94-5.24) for 68Ga-uPAR and 15.7 (range, 4.24-45.5) for 18F-FDG. The optimal cutoffs for 68Ga-NOTA-AE105 SUVmax in the primary tumor were 2.63 for RFS and 2.66 for OS. A high uptake of 68Ga-NOTA-AE105 (SUVmax above cutoff) was significantly associated with poor RFS and OS (log-rank P = 0.012 and P = 0.022). 68Ga-NOTA-AE105 uptake in the primary tumor was significantly associated with poor RFS in univariate analysis (hazard ratio [HR], 8.53 [95% CI, 1.12-64.7]; P = 0.038), and borderline-associated with OS (HR, 7.44 [95% CI, 0.98-56.4]; P = 0.052). For 18F-FDG PET, the optimal cutoffs were 22.7 for RFS and 22.9 for OS. An 18F-FDG SUVmax above the cutoff was significantly associated with reduced RFS (log-rank P = 0.012) and OS (log-rank P = 0.000). 18F-FDG uptake was significantly associated with reduced RFS (HR, 3.27 [95% CI, 1.237-8.66]; P = 0.017) and OS (HR, 7.10 [95% CI, 2.60-19.4]; P < 0.001) in univariate analysis. In a multivariate analysis including 68Ga-uPAR SUVmax, 18F-FDG SUVmax, TNM stage, and p16 status, only 68Ga-uPAR SUVmax remained significant (HR, 8.51 [95% CI, 1.08-66.9]; P = 0.042) for RFS. For OS, only TNM stage and 18F-FDG remained significant. Conclusion: The current trial showed promising results for the use of 68Ga-uPAR PET SUVmax in the primary tumor to predict RFS in head and neck squamous cell carcinoma patients referred for curatively intended radiotherapy when compared with 18F-FDG PET, TNM stage, and p16 status. 68Ga-uPAR PET could potentially become valuable for identification of patients suited for deescalation of treatment and risk-stratified follow-up schemes.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Risør LM, Clausen MM, Ujmajuridze Z, et al. Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with 18F-FDG PET/CT: A Single-Center Prospective Study. J Nucl Med. 2021. PMID: 34857658. doi:10.2967/jnumed.121.262866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。